Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
01/23/18 12:06 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients01/17/18
Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program12/21/17
Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences11/22/17
Investor Events More
There are currently no events scheduled.